Business UpdateMay 28, 2026, 10:16 AM
ProMIS Neurosciences to Present at 5 June Conferences; PMN310 Data Q3 2026
AI Summary
ProMIS Neurosciences Inc. announced its participation in five healthcare conferences in June 2026, including the Jefferies Global Healthcare Conference and BIO International Convention. CEO Neil Warma will present on the company's EpiSelect™ platform and its lead Alzheimer's disease candidate, PMN310. The company also reiterated its expectation to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data anticipated in early 2027.
Key Highlights
- ProMIS Neurosciences will participate in 5 upcoming June 2026 conferences.
- CEO Neil Warma will discuss the EpiSelect™ platform and lead AD candidate PMN310.
- PMN310 is designed to selectively target toxic amyloid-beta oligomers in Alzheimer's disease.
- Blinded 6-month interim data from the PRECISE-AD Phase 1b trial is expected in early Q3 2026.
- 12-month topline data from the Phase 1b trial is anticipated in early 2027.
- Conferences include Jefferies, Wolfe Research, Oppenheimer, H.C. Wainwright, and BIO International.
Price Impact
More from PMN